Last reviewed · How we verify

Acute Ischemic Stroke — Treatment Landscape & Competitive Intelligence

Acute Ischemic Stroke (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Ischemic Stroke, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Best Available Treatment best-available-treatment Pfizer Not specified Not specified
No OAC no-oac Pfizer Direct Oral Anticoagulant Factor Xa
PF-07976016 Formulation A pf-07976016-formulation-a Pfizer Unknown Unknown

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Acute Ischemic Stroke

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Ischemic Stroke:

Cite this brief

Drug Landscape (2026). Acute Ischemic Stroke — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-ischemic-stroke. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing